Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301 [clinicaltrials:NCT00149929]

Bio2RDF uri

Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301 [clinicaltrials:NCT00149929]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00149929

Bio2RDF identifier

NCT00149929

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00149929

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00149929

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

246

http://www.w3.org/2001/XMLSchema#integer

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

Aim of study is to coll ...... d mycophenolate sodium.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Follow-up Study of Safety of E ...... ly Completed Study CERL080A301

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Incidence of biopsy proven acute rejection, graft loss, or death in the first six months of treatment. [clinicaltrials_resource:96c2cca405c326139e96d77b9351f0bb]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Incidence of biopsy proven acute rejection, graft loss, or death in the first six months of treatment. [clinicaltrials_resource:20fcb88ddc752e67dcda79a5f74b9cfd]

Incidence of biopsy proven acute rejection, graft loss, or death in the first six months of treatment. [clinicaltrials_resource:9a8b904ec612e61baf5bba2b7f12a512]

Incidence of biopsy proven acute rejection, graft loss, or death in the first six months of treatment. [clinicaltrials_resource:b6d08bfa846fc02920e1f881cd0c858e]

Incidence of biopsy proven acute rejection, graft loss, or death in the first six months of treatment. [clinicaltrials_resource:ff8b8b8155d188e5c5fcae604d46812f]

completion date [clinicaltrials_vocabulary:completion-date]

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Renal Transplant [clinicaltrials_resource:96dd602598ba203a1b0122a99c32ead2]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00149929 [clinicaltrials_resource:22a9af5e9b8f64939215ad790184d0e0]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

intervention [clinicaltrials_vocabulary:intervention]

Mycophenolate sodium (enteric coated) [clinicaltrials_resource:9133e0d703815903bf0f4f04a822b9eb]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Mycophenolate mofetil [clinicaltrials_resource:31de209b7264303fdda3c8b57bf0b039]

Mycophenolic Acid [clinicaltrials_resource:f75b029fbf569731a07aa713250d93da]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Renal Transplant, adults, immunosuppressant

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Novartis [clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00149929

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

Multicenter, Open-label Follow ...... Novo Renal Transplant Patients

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CERL080A301E

http://www.w3.org/2001/XMLSchema#string

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

Novartis, Novartis [clinicaltrials_resource:6d8c029072ce4da24caccc964c0f4d1f]

source [clinicaltrials_vocabulary:source]

Novartis [clinicaltrials_resource:4b711ffdbe8af5c8f3f9c53da46d83fa]

start date [clinicaltrials_vocabulary:start-date]

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00149929 study design [clinicaltrials_resource:74d8b368610dec0d8b7d84f53bf14509]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00149929

verification date [clinicaltrials_vocabulary:verification-date]

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00149929

http://www.w3.org/2001/XMLSchema#string

title

Follow-up Study of Safety of E ...... ly Completed Study CERL080A301

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Follow-up Study of Safety of E ...... 1 [clinicaltrials:NCT00149929]

@en